ASCs in Recently Diagnosed Non-ischemic Heart Failure

Summary

The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in restoring cardiac function compared to placebo. The primary outcome of this trial is the change in left ventricular ejection fraction 6 month after treatment compared to placebo. Participants will be given two treatments with one month apart of either allogeneic adipose tissue-derived mesechymal stromal cells or placebo.

Timeline

Start

2026-03-01

Primary completion

2028-09-01

Completion

2028-09-01

Outcome

Outcome not reported

Stopped: “Due to changes in company structure and investment the trial will not be initiated.”

Publications

• Chaaban N, Kastrup J, Rossing K, Schou M, Hove J, Buch P, Ekblond A, Johansen EM, Norgaard MJ, Hojgaard LD, Qayyum AA. Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design. Future Cardiol. 2026 Apr;22(4):353-361. doi: 10.1080/14796678.2026.2647879. Epub 2026 Mar 25.

Drugs

Indications